Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

TitleTreatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Publication TypeJournal Article
Year of Publication2013
AuthorsRaghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery BA, Chien JW, O'Riordan TG
Corporate AuthorsARTEMIS-IPF Investigators*
JournalAnnals of internal medicine
Volume158
Issue9
Pagination641-9
Date Published2013 May 7
Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.

DOI10.1007/s11356-013-1768-9
Alternate JournalAnn. Intern. Med.